





Kopran



PARIJAT
ENTERPRISES



ONEDIRECTION, ENDLESS OPPORTUNITIES.

CORPORATE PRESENTATION
Q3 FY 2023-24

KOPRAN LIMITED

This quarterly investor presentation has been prepared by Kopran Limited ('Kopran') and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be 'forward-looking statements', including those relating to the general business plans and strategy of Kopran, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks with respect to API and Formulation businesses.

Kopran may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

An integrated Pharmaceutical Company, committed to supplying International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally

State-of-the-art manufacturing facilities and products with various accreditations and approvals by major global regulatory authorities

The formulations vertical is operated through Kopran Limited

The API vertical is being operated under Kopran Research Laboratories Ltd. (KRLL), a wholly owned subsidiary of Kopran Limited

50+

Nations - Export Reach

Technology-focused Company

Serving Regulated and Non-Regulated Markets



State-of-the-art Manufacturing Facilities

API VERTICAL

Development, manufacturing and sale of diverse APIs and Advanced Intermediates

One of the leaders in Atenolol

One of the major players in Sterile Carbapenems

World-class facility and quality systems

Catering export and domestic market

DEDICATED AND VERSATILE FACILITIES FOR

Atenolol

Cephalosporins - Non-Sterile & Sterile

Macrolides

Granules

Sterile Carbapenems

Multipurpose plants

Pilot plants

PRODUCT SEGMENTS

Anti-hypertensive

Macrolide

Neuromodulator

Urological

Anti-infective/Anti-acne

Sterile Carbapenem

Sterile Cephalosporin

Anti-thrombotic

Intermediate

Anti-diabetic

FACILITY

Located at
**MIDC Mahad,
Maharashtra**

11,900 sq. mts.
built-up area

26

Products commercialised



PRODUCT SEGMENTS

PENICILLIN-BASED FINISHED ORAL DOSAGE FORMS

Anti-infective
Amoxicillin
Ampicillin
Cloxacillin
Amoxy Clav

NON-PENICILLIN-BASED FINISHED ORAL DOSAGE FORMS

Macrolides
Anti-hypertensive
Cardiovascular
Anti-helmentics
Anti-histamine
EDS
Anti-diabetic
CNS
Pain Management
Gastroenterology



FORMULATIONS VERTICAL

Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs

Catering 100% export markets of both Regulated and Non-Regulated markets

Manufacturers of more than 100 dosages meeting the standards of international markets which includes Tablets, Capsules, Dry Powder and Suspension


DEDICATED FACILITIES

- Penicillin-based finished oral dosage forms
- Non-Penicillin-based finished oral dosage forms

FACILITY

Located at
**Khopoli,
Maharashtra**

11,432 sq. mts.
built-up area



OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE




FORMULATIONS ACCREDITATIONS

Approved by 15 countries including MHRA (UK), SAPHRA South Africa (formerly MCC), MMA Malta (EU GMP), Health Canada (Canada), FDA Philippines, DAV Vietnam, FDA Thailand, TMDA Tanzania (formerly TFDA), NDA Uganda, PPB Kenya, EFDA Ethiopia, MCAZ Zimbabwe, MOH Oman, MOH Iraq, MOH Yemen

The Company maintains highest global regulatory standards of manufacturing and quality at its all plants

API ACCREDITATIONS

The plant has been approved by



*Except sterile facility

OPERATIONAL PERFORMANCE



Kopran Research Laboratories Limited
उच्च उत्पादकता और गुणवत्ता हमारा लक्ष; सुरक्षितता में रहे हम सदैव दक्ष
OUR "COMMITMENT" SAFE AND GREEN ENVIRONMENT

OUR "COMMITMENT" SAFE AND GREEN ENVIRONMENT

Single women
and child only
NO ENTRY
WORKERS STRICTLY
PROHIBITED


ELECTRICAL DEPT.
POLYMER DEPT.
POLYMER
WATER SYSTEM

EHS
Kopran

Site Plan

Q3 FY 2023-24 (₹ LAKHS)


- Anti- Infective
- Antibiotic-Urological
- Anti-Hypertensive
- Neuromodulator
- Steriles Cephalosporin
- Macrolide
- Carbapenem
- Anti-Thrombotic
- Intermediate



Total ₹ 8,117 Lakhs

9M FY 2023-24 (₹ LAKHS)


- Anti- Diabetic
- Anti- Infective
- Antibiotic-Urological
- Anti-Hypertensive
- Neuromodulator
- Steriles Cephalosporin
- Macrolide
- Carbapenem
- Anti-Thrombotic
- Intermediate



Total ₹ 23,848 Lakhs


Note: Excluding solvent and scrap sales and includes API consumed for production of formulations.

Q3 FY 2023-24 (₹ LAKHS)



Total ₹ **8,117** Lakhs

9M FY 2023-24 (₹ LAKHS)




Total ₹ **23,848** Lakhs

Note: Excluding solvent and scrap sales and includes API consumed for production of formulations.

Q3 FY 2023-24 (₹ LAKHS)


- Africa
- Canada
- Latem
- South Africa
- Southeast Asia
- UK
- Middle East and North Africa



Total ₹ **7,679** Lakhs

9M FY 2023-24 (₹ LAKHS)


- Africa
- Canada
- Latem
- South Africa
- Southeast Asia
- UK
- Middle East and North Africa



Total ₹ **18,908** Lakhs


Note: Excluding Scrap Sales

Q3 FY 2023-24 (₹ LAKHS)



Total ₹ **7,679** Lakhs

9M FY 2023-24 (₹ LAKHS)



Total ₹ **18,908** Lakhs

Note: Excluding Scrap Sales

FINANCIAL PERFORMANCE




PARTICULARS	Q3 FY 2023-24	Q2 FY 2023-24	Q3 FY 2022-23
Revenue from Operations	16,135	15,259	16,022
EBITDA	2,358	2,283	1,384
Net Profit	1,579	1,377	661


PARTICULARS	9M FY 2023-24	H1 FY 2023-24	FY 2022-23
Net Debt: Equity	0.19	0.20	0.14
RoCe (%)	12.1	9.0	7.9

Summary

- Revenue from operations increased to ₹ 16,135 Lakhs in Q3 FY 2023-24 as compared to ₹ 16,022 Lakhs in Q3 of FY 2022-23.
- EBITDA grew from ₹ 1,384 Lakhs in Q3 of FY 2022-23 to ₹ 2,358 Lakhs during the third quarter of the current financial year.
- Net Profit grew by 139% to record ₹ 1,579 Lakhs as against ₹ 661 Lakhs in Q3 of FY 2022-23.
- The EBITDA margins also improved due to better product mix.




SALES/OTHER INCOME
(₹ LAKHS)



FINANCE COSTS
(₹ LAKHS)

NET PROFIT/(LOSS)
(₹ LAKHS)



EBITDA *
(₹ LAKHS)




NET PROFIT/(LOSS)
(₹ LAKHS)


Note: EBITDA excluding other income

EBITDA & EBITDA Margin

(₹ Lakhs, %)




RoE (%) RoCE (%)



Net Debt/Equity

(X)



CONSOLIDATED FINANCIAL HIGHLIGHTS

PARTICULARS	9M FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue from Operations	42,851	55,098	47,752	49,181	35,949
Equity Share Capital	4,821	4,821	4,821	4,325	4,324
Other Equity	42,555	39,104	37,796	20,177	14,643
Net Worth	47,376	43,925	42,617	24,503	18,968
Fixed Assets(net)	25,991	23,457	18,623	15,508	14,139
Borrowings	9,823	7,524	7,248	6,429	7,806
EBITDA	5,272	5,180	8,739	8,178	4,696
Finance Costs	601	608	512	623	891
Depreciation	929	1,271	1,110	1,019	957
Tax Expenses	1,003	883	2,075	2,172	726
Net Profit	3,234	2,723	6,103	6,183	2,120
Earnings Per Share(Rs)	6.71	5.65	13.77	14.24	4.86

Note: EBITDA excluding other income



MR. SURENDRA SOMANI
EXECUTIVE VICE CHAIRMAN



MR. ADARSH RAJENDRA SOMANI
DIRECTOR



MRS. MAMTA BIYANI
INDEPENDENT DIRECTOR



MR. NARAYAN ATAL
INDEPENDENT DIRECTOR



DR. SIDDHAN SUBRAMANIAN
INDEPENDENT DIRECTOR



DR. SUNITA BANERJI
INDEPENDENT DIRECTOR



MR. SUSHEEL SOMANI
DIRECTOR



MR. VARUN SURENDRA SOMANI
DIRECTOR

ABOUT KOPRAN LIMITED:

Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New Products and Processes for both Formulations & APIs form the strategy of Kopran's growth.

REGISTERED OFFICE:

Parijat House,
1076, Dr. E. Moses Road,
Worli, Mumbai – 400 018,
Maharashtra (India)

Corporate Identification No.:
L24230MH1958PLC011078

For more information about us, please visit
www.kopran.com
or contact:

Name: Sunil Sodhani
Tel.: +91 8692991999
Email: sunil@kopran.com

